EXTENDED REPORT

Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists

R Landewé, B Rump, D van der Heijde, S van der Linden

University Hospital Maastricht, Department of Internal Medicine/Rheumatology, Maastricht, Netherlands

Correspondence to:
Correspondence to:
Robert B M Landewé
Department of Internal Medicine/Rheumatology, PO Box 5800, 6202 AZ Maastricht, Netherlands; rlan{at}sint.azm.nl

Aim: To determine the criteria considered important by Dutch rheumatologists in judging whether a patient with ankylosing spondylitis should start tumour necrosis factor (TNF) blocking therapy.

Methods: 19 Dutch rheumatologists were asked to prioritise various demographic and clinical features for their importance in judging whether a patient should be treated with TNF blocking therapy. In addition, nine Dutch physicians who had referred patients with ankylosing spondylitis for inclusion in an ongoing long term observational study (OASIS) were asked to determine on the basis of case record review for each of their patients whether or not TNF blocking therapy would be considered appropriate.

Results: The variables considered most important were: rate of development of functional impairment; physician’s global assessment of current disease activity; physician’s global assessment of cumulative disease activity; presence of hip arthritis; physician’s global assessment of disease severity. Analysis of the OASIS data (79 patients) showed that patients in whom TNF blocking therapy was considered justified (n = 24; 30%) differed significantly from those in whom it was not considered justified in: patient reported disease activity; functional impairment; spinal mobility; radiographic damage score. Multivariate analysis showed that male sex, function, and radiographic damage were the only independent determinants of a decision to start TNF blocking drugs.

Conclusions: Physicians reported that disease activity, function, and severity were critically important in judging whether to start TNF blocking therapy. In practice, they based their decision more on severity than on activity. They were able to select patients with a high level of radiographic damage, which suggests that this feature captures other domains such as disease activity, spinal mobility, and function.

Keywords: ankylosing spondylitis; anti-TNF therapy; spinal mobility

Abbreviations: BASDAI, Bath ankylosing spondylitis disease activity index; ISSAS, "International start TNF blocker study ankylosing spondylitis"; OASIS, "Outcome in ankylosing spondylitis international study"; SASSS, Stoke ankylosing spondylitis spinal score; TNF, tumour necrosis factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• van der Heijde, D, Landewe, R, Feldtkeller, E (2008). Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 67: 489-493 [Abstract] [Full Text]  
• Cruyssen, B. V., Ribbens, C., Boonen, A., Mielants, H., de Vlam, K., Lenaerts, J., Steinfeld, S., Van den Bosch, F., Dewulf, L., Vastesaeger, N. (2007). The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 66: 1072-1077 [Abstract] [Full Text]  
• Pham, T, Landewe, R, van der Linden, S, Dougados, M, Sieper, J, Braun, J, Davis, J, Rudwaleit, M, Collantes, E, Burgos-Vargas, R, Edmonds, J, Olivieri, I, van der Horst-Bruinsma, I, Mielants, H, Stone, M, Emery, P, van der Heijde, D (2006). An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis 65: 1620-1625 [Abstract] [Full Text]  
• Boonen, A, van der Heijde, D, Severens, J L, Boendermaker, A, Landewe, R, Braun, J, Brandt, J, Sieper, J, van der Linden, S. (2006). Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 65: 201-208 [Abstract] [Full Text]  
• Spoorenberg, A., van Tubergen, A., Landewe, R., Dougados, M., van der Linden, S., Mielants, H., van de Tempel, H., van der Heijde, D. (2005). Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford) 44: 789-795 [Abstract] [Full Text]